UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

Hepatology (Baltimore, Md.), 2016-08, Vol.64 (2), p.381-389

2016

Volltextzugriff (PDF)

Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir

Alimentary pharmacology & therapeutics, 2019-01, Vol.49 (2), p.218-228

2019

Volltextzugriff (PDF)

Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma

Journal of hepatology, 2012-02, Vol.56 (2), p.412-418

2012

Volltextzugriff (PDF)

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment

PloS one, 2019-10, Vol.14 (10), p.e0222221-e0222221

2019

Volltextzugriff (PDF)

Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death

Gastroenterology (New York, N.Y. 1943), 2010-05, Vol.138 (5), p.1747-1754.e1

2010

Volltextzugriff (PDF)

Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B

Alimentary pharmacology & therapeutics, 2023-08, Vol.58 (3), p.334-345

2023

Volltextzugriff (PDF)

Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients

Alimentary pharmacology & therapeutics, 2024-04, Vol.59 (8), p.993-1002

2024

Volltextzugriff (PDF)

Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study

Gastroenterology (New York, N.Y. 1943), 2010-08, Vol.139 (2), p.474-482

2010

Volltextzugriff (PDF)

Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non‐alcoholic fatty liver disease

Liver international, 2023-09, Vol.43 (9), p.1901-1908

2023

Volltextzugriff (PDF)

Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan

Gastroenterology (New York, N.Y. 1943), 2008-07, Vol.135 (1), p.111-121

2008

Volltextzugriff (PDF)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals

PloS one, 2019-04, Vol.14 (4), p.e0214323-e0214323

2019

Volltextzugriff (PDF)

Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients

The Kaohsiung journal of medical sciences, 2024-06, Vol.40 (6), p.589-598

2024

Volltextzugriff (PDF)

Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer–Specific Mortality in a Large Nationwide Cohort

Hepatology (Baltimore, Md.), 2021-10, Vol.74 (4), p.1994-2006

2021

Volltextzugriff (PDF)

The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients

Journal of viral hepatitis, 2021-08, Vol.28 (8), p.1141-1149

2021

Volltextzugriff (PDF)

Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population‐based study

Alimentary pharmacology & therapeutics, 2018-11, Vol.48 (9), p.993-1002

2018

Volltextzugriff (PDF)

Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation

PloS one, 2020-11, Vol.15 (11), p.e0242113-e0242113

2020

Volltextzugriff (PDF)

Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C

Journal of clinical oncology, 2011-09, Vol.29 (27), p.3643-3650

2011

Volltextzugriff (PDF)

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting

PloS one, 2022-08, Vol.17 (8), p.e0272567

2022

Volltextzugriff (PDF)

Letter: the association between chronic viral hepatitis and metabolic syndrome – Authors' reply

Alimentary pharmacology & therapeutics, 2019-01, Vol.49 (2), p.233-234

2019

Volltextzugriff (PDF)

Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL

Scientific reports, 2017-05, Vol.7 (1), p.1839-9, Article 1839

2017

Volltextzugriff (PDF)

Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study

Hepatology (Baltimore, Md.), 2017-09, Vol.66 (3), p.784-793

2017

Volltextzugriff (PDF)

Editorial: hepatitis B, fatty liver and metabolic syndrome—Interaction or co‐existence? Authors’ reply

Alimentary pharmacology & therapeutics, 2018-11, Vol.48 (10), p.1162-1163

2018

Volltextzugriff (PDF)

Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy

Virology journal, 2024-04, Vol.21 (1), p.79-79, Article 79

2024

Volltextzugriff (PDF)

Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma

Clinical gastroenterology and hepatology, 2013-12, Vol.11 (12), p.1636-1645.e3

2013

Volltextzugriff (PDF)

Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan

Alimentary pharmacology & therapeutics, 2020-12, Vol.52 (11-12), p.1695-1706

2020

Volltextzugriff (PDF)

1 – 25 von 885

Suche als RSS-Feed

Aktive Filter

SpracheChinesisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(820)
Mit Volltextzugriff
(775)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(708)
Life Sciences & Biomedicine
(512)
Humans
(479)
Male
(399)
Female
(387)
Middle Aged
(363)
Adult
(279)
Aged
(244)
Gastroenterology & Hepatology
(209)
Hepatocellular Carcinoma
(165)
Biological And Medical Sciences
(137)
Risk Factors
(137)
Medical Sciences
(128)
Science & Technology - Other Topics
(117)
Patients
(116)
Hepatitis
(115)
Multidisciplinary Sciences
(114)
Hepatitis B Virus
(111)
Retrospective Studies
(108)
Liver Cancer
(102)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression

Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir

Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment

Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death

Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B

Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients

Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study

Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non‐alcoholic fatty liver disease

Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals

Role of reimbursement and Physicians' awareness in the survival of sorafenib‐eligible advanced hepatocellular carcinoma patients

Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer–Specific Mortality in a Large Nationwide Cohort

The role of hepatitis B virus core‐related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen‐negative patients

Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population‐based study

Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation

Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting

Letter: the association between chronic viral hepatitis and metabolic syndrome – Authors' reply

Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL

Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study

Editorial: hepatitis B, fatty liver and metabolic syndrome—Interaction or co‐existence? Authors’ reply

Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy

Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma

Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan

Aktive Filter

Suchergebnisse filtern